GB0401336D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0401336D0
GB0401336D0 GBGB0401336.3A GB0401336A GB0401336D0 GB 0401336 D0 GB0401336 D0 GB 0401336D0 GB 0401336 A GB0401336 A GB 0401336A GB 0401336 D0 GB0401336 D0 GB 0401336D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
alkoxy
hydrogen
compounds
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0401336.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0401336(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0401336.3A priority Critical patent/GB0401336D0/en
Publication of GB0401336D0 publication Critical patent/GB0401336D0/en
Priority to PT05706936T priority patent/PT1709036E/pt
Priority to CA002553010A priority patent/CA2553010A1/en
Priority to BRPI0506927-0A priority patent/BRPI0506927A/pt
Priority to DE602005005161T priority patent/DE602005005161T2/de
Priority to KR1020067014629A priority patent/KR20060129276A/ko
Priority to US10/585,614 priority patent/US20090233938A1/en
Priority to EP05706936A priority patent/EP1709036B1/en
Priority to PL05706936T priority patent/PL1709036T3/pl
Priority to PCT/EP2005/000542 priority patent/WO2005070926A1/en
Priority to ES05706936T priority patent/ES2300985T3/es
Priority to AU2005206290A priority patent/AU2005206290B2/en
Priority to JP2006550041A priority patent/JP2007518767A/ja
Priority to CN2005800026886A priority patent/CN1910178B/zh
Priority to AT05706936T priority patent/ATE388147T1/de
Priority to RU2006130002/04A priority patent/RU2374242C2/ru
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0401336.3A 2004-01-21 2004-01-21 Organic compounds Ceased GB0401336D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0401336.3A GB0401336D0 (en) 2004-01-21 2004-01-21 Organic compounds
RU2006130002/04A RU2374242C2 (ru) 2004-01-21 2005-01-20 Производные тиазола в качестве антагонистов а2в
AT05706936T ATE388147T1 (de) 2004-01-21 2005-01-20 Thiazolderivate als a2b-antagonisten
EP05706936A EP1709036B1 (en) 2004-01-21 2005-01-20 Thiazole derivatives as a2b antagonists
PL05706936T PL1709036T3 (pl) 2004-01-21 2005-01-20 Pochodne tiazolu jako substancje antagonistyczne wobec A2B
BRPI0506927-0A BRPI0506927A (pt) 2004-01-21 2005-01-20 compostos orgánicos
DE602005005161T DE602005005161T2 (de) 2004-01-21 2005-01-20 Thiazolderivate als a2b-antagonisten
KR1020067014629A KR20060129276A (ko) 2004-01-21 2005-01-20 Ａ２ｂ 길항제로서의 티아졸 유도체
US10/585,614 US20090233938A1 (en) 2004-01-21 2005-01-20 Thiazole derivatives as a2b antagonists
PT05706936T PT1709036E (pt) 2004-01-21 2005-01-20 Derivados do tiazole como antagonistas a2b
CA002553010A CA2553010A1 (en) 2004-01-21 2005-01-20 Thiazole derivatives as a2b antagonists
PCT/EP2005/000542 WO2005070926A1 (en) 2004-01-21 2005-01-20 Thiazole derivatives as a2b antagonists
ES05706936T ES2300985T3 (es) 2004-01-21 2005-01-20 Derivados de tiazol como antagonistas de a2b.
AU2005206290A AU2005206290B2 (en) 2004-01-21 2005-01-20 Thiazole derivatives as A2b antagonists
JP2006550041A JP2007518767A (ja) 2004-01-21 2005-01-20 Ａ２ｂアンタゴニストとしてのチアゾール誘導体
CN2005800026886A CN1910178B (zh) 2004-01-21 2005-01-20 作为a2b拮抗剂的噻唑衍生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0401336.3A GB0401336D0 (en) 2004-01-21 2004-01-21 Organic compounds

Publications (1)

Publication Number Publication Date
GB0401336D0 true GB0401336D0 (en) 2004-02-25

Family

ID=31971241

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0401336.3A Ceased GB0401336D0 (en) 2004-01-21 2004-01-21 Organic compounds

Country Status (16)

Country Link
US (1) US20090233938A1 (enExample)
EP (1) EP1709036B1 (enExample)
JP (1) JP2007518767A (enExample)
KR (1) KR20060129276A (enExample)
CN (1) CN1910178B (enExample)
AT (1) ATE388147T1 (enExample)
AU (1) AU2005206290B2 (enExample)
BR (1) BRPI0506927A (enExample)
CA (1) CA2553010A1 (enExample)
DE (1) DE602005005161T2 (enExample)
ES (1) ES2300985T3 (enExample)
GB (1) GB0401336D0 (enExample)
PL (1) PL1709036T3 (enExample)
PT (1) PT1709036E (enExample)
RU (1) RU2374242C2 (enExample)
WO (1) WO2005070926A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
NZ566036A (en) * 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
JP5026511B2 (ja) 2006-05-18 2012-09-12 エフ．ホフマン−ラ ロシュ アーゲー アデノシンａ２ｂレセプターアンタゴニストとしてのチアゾロ−ピラミジン／ピリジン尿素誘導体
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
ES2424023T3 (es) 2007-10-18 2013-09-26 Janssen Pharmaceutica N.V. 1,2,4-triazoles trisustituidos
MY152486A (en) 2008-03-19 2014-10-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators
US8779158B2 (en) 2008-05-09 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
WO2019072143A1 (zh) * 2017-10-11 2019-04-18 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
WO2020083957A1 (en) 2018-10-24 2020-04-30 Leadxpro Ag Functionalized aminotriazines
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
US20250101013A1 (en) * 2022-01-19 2025-03-27 Leadxpro Ag Functionalized aminothiazoles
GB2615307A (en) * 2022-01-28 2023-08-09 Adorx Therapeutics Ltd Antagonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
WO1999064418A1 (en) * 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
JP2000281685A (ja) * 1999-01-28 2000-10-10 Takeda Chem Ind Ltd チアゾロピリミジン化合物、その製造法および用途
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JP2002302445A (ja) * 2001-02-02 2002-10-18 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
JP2005510508A (ja) * 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類

Also Published As

Publication number Publication date
US20090233938A1 (en) 2009-09-17
WO2005070926A1 (en) 2005-08-04
ES2300985T3 (es) 2008-06-16
JP2007518767A (ja) 2007-07-12
CN1910178B (zh) 2010-06-02
RU2374242C2 (ru) 2009-11-27
PL1709036T3 (pl) 2008-08-29
EP1709036B1 (en) 2008-03-05
KR20060129276A (ko) 2006-12-15
PT1709036E (pt) 2008-05-28
ATE388147T1 (de) 2008-03-15
AU2005206290A1 (en) 2005-08-04
CA2553010A1 (en) 2005-08-04
CN1910178A (zh) 2007-02-07
DE602005005161T2 (de) 2009-03-19
DE602005005161D1 (de) 2008-04-17
AU2005206290B2 (en) 2008-12-04
EP1709036A1 (en) 2006-10-11
BRPI0506927A (pt) 2007-06-05
RU2006130002A (ru) 2008-02-27

Similar Documents

Publication Publication Date Title
MY126139A (en) Piperidine compounds for use as ccr-3 inhibitors
GB0401336D0 (en) Organic compounds
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2013002558A (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
WO2008136444A1 (ja) 縮合複素環誘導体
UA105185C2 (uk) Піроли
ECSP034611A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina
EP1338595A3 (en) Xanthine derivatives as DPP-IV inhibitors
SG160195A1 (en) N-phenyl-2-pyrimidine-amine derivatives
TW200716575A (en) 1,3,5-triazine derivative, method for producing the same, and organic electroluminescent device containing the same as component
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
HRP20090061T3 (en) Purine derivatives acting as a2a receptor agonists
TW200602456A (en) Anthracene compound and organic electroluminescent device including the anthracene compound
TW200724528A (en) Carbazole derivative, light-emitting element material obtained by using carbazole derivative, light-emitting element, and electronic device
TW200609670A (en) Pyridone azo compound, tautomer thereof, and colorant-containing curable composition, color filter and manufacturing method thereof
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
CA2461060A1 (en) Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
TW200726750A (en) Stilbene derivatives, light-emitting element and light-emitting device
TNSN08161A1 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
TW200637870A (en) Novel pyrimidine nucleoside compound and salt thereof
UA107457C2 (uk) Похідні піразолу
EA200700767A1 (ru) Способ получения пиразолов

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)